Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep, Notice of Ceasing to be a Substantial Holder (ASX:IMM)

Form 605 To view Notice please download PDF attached:

Immutep, IMP761 Webcast Slides (ASX:IMM)

Date & Time: March 26, 2019, 7:45 am Australian Eastern Daylight Time March 25, 2019, 4:45 pm US Eastern Daylight Time The LAG-3 Agonist Concept IMP761: In Vitro Testing IMP761: In Vivo T...read more

Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer (ASX:IMM)

SYDNEY, AUSTRALIA – 22 March 2019 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treat...read more

Imugene announces Imugene’s Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx Immunotherapy Clinical Development Plan (ASX:IMU)

Sydney, Australia, 20 March 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced it had received and accepted the minutes of its Pre-Investigational New Drug (IND...read more

Immutep announces Webcast to discuss IMP761 preclinical results (ASX:IMM)

Immutep to Present IMP761 Preclinical Results in Global Webcast SYDNEY, AUSTRALIA – March 19, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company...read more

Imugene Announces First Patient Dosed in the Open-Label Phase 2 Study with HER-Vaxx Cancer Vaccine for Advanced Gastric Cancer (ASX:IMU)

First patient dosed in 68 patient Randomised Phase 2 HER-Vaxx cancer trial Two Eastern European sites now actively recruiting Approval imminent for trial sites in Hong Kong, Taiwan,...read more

Immutep Announces Positive IMP761 Preclinical Results Presented at 14th Congress of European Crohn’s and Colitis Organisation (ASX:IMM)

SYDNEY, AUSTRALIA – 8 March 2019 - Immutep Limited (ASX:IMM; NASDAQ:IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune di...read more

Immutep Announces A$872,351 R&D Tax Incentive Received (ASX:IMM)

SYDNEY, AUSTRALIA - Immutep Limited (ASX:IMM;NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$872,351 cash rebate from the Australian...read more

Immutep Announces First Patient Dosed in TACTI-002 Phase II Trial (ASX:IMM)

The First Patient has been dosed at “START Madrid- FJD” in Spain Clinical trial sites are active and more will be activated and commence recruitment in coming months SYDNEY, AUSTRA...read more

Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma (ASX:IMM)

Presented at the World Immunotherapy Congress USA 2019 SYDNEY, AUSTRALIA – 6 March 2019 - Immutep Limited (ASX:IMM; NASDAQ:IMMP) (Immutep or the Company), a biotechnology company developing n...read more

Immutep Announces Presentation at Oppenheimer’s 29th Annual Healthcare Conference (ASX:IMM)

SYDNEY, AUSTRALIA – 04 March 2019 - Immutep Limited (ASX:IMM; NASDAQ:IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune d...read more

Imugene Announces Presentations on Lead PD-1 and HER-2 Cancer Vaccines at the American Association for Cancer Research 2019 Annual Meeting (ASX:IMU)

SYDNEY, Australia, 4 March 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Tanios Bekaii-Saab from the Mayo Clinic will present on the KEY-Vaxx and B-Vaxx...read more

Imugene Announces Presentation on HER-Vaxx Cancer Vaccine at the American Association for Cancer Research 2019 Annual Meeting (ASX:IMU)

SYDNEY, Australia, 28 February 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Professor Ursula Wiedermann will present on the HER-Vaxx cancer vaccine at the...read more

Immutep, Appendix 4D Interim Financial Report for the Half Year Ended 31 December 2018 (ASX:IMM)

Contents - Directors’ Report - Auditor’s Independence Declaration - Consolidated Statement of Comprehensive Income - Consolidated Balance Sheet - Consolidated Statement of C...read more

Integrated Payment Technologies, Financial Report for the Half Year Ended 31 December 2018 (ASX:IP1)

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of Integrated Payment Technologies Limi...read more

Viewing: 1 - 15 of 200 Previous | Next